Inspire Medical Systems, Inc. (INSP) PT Reduced to $64 as Truist Updates MedTech Outlook Ahead of Q1

We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. Inspire Medical Systems, Inc. is among the most undervalued stocks to invest in.

TheFly reported on April 15 that Truist Financial reduced its price target for INSP from $70 to $64 while maintaining a Hold stance on the stock. The adjustment was made within a broader outlook on MedTech ahead of first-quarter results, with expectations that performance may meet or slightly exceed cautious investor sentiment around procedure volumes. However, the firm noted that the current valuation discount versus peers appears warranted due to near-term growth uncertainty, particularly linked to slowing domestic expansion and ongoing reimbursement-related challenges.

Inspire Medical Systems, Inc. (INSP) PT Reduced to $64 as Truist Updates MedTech Outlook Ahead of Q1

Similarly, a day earlier on April 14, Royal Bank of Canada revised its outlook on Inspire Medical Systems, Inc. (NYSE:INSP) and lowered its price target from $68 to $56 while maintaining a Sector Perform rating. This update also came as part of a broader MedTech sector review ahead of first-quarter earnings. Despite acknowledging stable underlying demand conditions and generally solid fundamentals with no signs of major market disruption, the firm highlighted that recent sentiment-driven weakness may be overstated. At the same time, it pointed to operational pressures affecting utilization and new center growth, including reimbursement coding challenges and delayed patient progression related to GLP-1 therapy trends, which limit near-term visibility across upcoming quarters.

In separate news, Inspire Medical Systems, Inc. (NYSE:INSP) will report its Q1 2026 results on May 4.

Inspire Medical Systems, Inc. (NYSE:INSP) is a medical technology company based in Minneapolis that develops implantable neurostimulation therapy for obstructive sleep apnea. It’s an FDA-approved device that stimulates the hypoglossal nerve as an alternative to CPAP treatment.

While we acknowledge the risk and potential of INSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than INSP and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 AI-Powered Biotech Stocks to Buy Right Now and 10 Most Undervalued Dow Stocks to Buy Now.

Disclosure: None. Follow Insider Monkey on Google News.